A panel made up of expert hematologists Ryan Cassaday, MD, Armin Ghobadi, MD, Elias Jabbour, MD, and Gary J. Schiller, MD discusses current standards-of-care in Acute Lymphoblastic Leukemia as well as key data presented at the American Society of Hematology’s 2022 Annual Meeting.
EP. 1: Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia
A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.
EP. 2: Differentiating Subtypes of Acute Lymphoblastic Leukemia
Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.
EP. 3: Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.
EP. 4: Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.
EP. 5: Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia
Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.
EP. 6: Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting
Focusing on Philadelphia chromosome-positive ALL, panelists review standard-of-care treatment practices.
EP. 7: The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.
EP. 8: Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.
EP. 9: Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Best practices and special considerations for effective therapy selection and sequencing in the relapsed/refractory ALL setting.
EP. 10: CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia
Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.
EP. 11: Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.
EP. 12: Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia
Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.
EP. 13: Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia
Led by Dr Armin Ghobadi, the panel reviews data from a study regarding CD19 CAR T-cell therapy use in adults with B-Cell ALL.
EP. 14: On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.